Silva. ‘For people with asthma, minimizing exposure to risk factors like tobacco smoke and polluting of the environment may delay disease progression to COPD. Effective antiinflammatory therapy at the onset of asthma may decrease the probability of COPD developing years afterwards also,’ added article coauthor Robert A. Barbee, MD, FCCP, University of Arizona, College of Medication. Experts caution that more analysis is needed to understand risk elements for progression and onset of COPD. No significant associations had been discovered between childhood and adulthood asthma onset and risk of acquiring chronic bronchitis, emphysema, or COPD. Likewise, no significant association was found between asthma duration and risk for lung disease.Schmidt, D.O., Pablo E. Pergola, M.D., Ph.D., Raja I. Zabaneh, M.D., Sandra Tong-Starksen, M.D., Martha R. Mayo, Pharm.D., Hong Tang, M.S., Krishna R. Polu, M.D., Anne-Marie Duliege, M.D., and Steven Fishbane, M.D. For the PEARL Study Groups: Peginesatide for Anemia in Individuals with Chronic Kidney Disease Not Receiving Dialysis The 1989 approval of recombinant individual erythropoietin facilitated sustained correction of anemia in chronic kidney disease and freed many sufferers undergoing dialysis from reliance on transfusions.1,2 Increases in hemoglobin amounts from approximately 6 to 7 g per deciliter to approximately 11 to 12 g per deciliter improved symptoms, quality of life, and physical capacity.3,4 Subsequent molecular modifications generated two erythropoiesis-stimulating agents with longer in vivo half-lives , offering the potential of less frequent administration.5-7 Both derive from the endogenous erythropoietin molecule.8 Peginesatide , a peptide-based ESA,9,10 was approved in the United States in March 2012 for the treatment of anemia caused by chronic kidney disease in adults who also are undergoing dialysis.